Background
Brian Rifkin
Why Can’t I Quit You: Steroid Tapering in ...

This week, we will discuss the best schedule for tapering steroids in adult patients with podocytopathies (MCD/FSGS).

Why Can’t I Quit You: Steroid Tapering in Adults with Podocytopathies (START)
Meta
joel topf
NephJC 2026 Fall Pledge Drive

Help keep NephJC a vital, original, and unbiased source of medical education.

NephJC 2026 Fall Pledge Drive
Background
Brian Rifkin
REFINe-ing AI’s Role in Nephrology Diagnosis

This week, we will discuss the use of LLMs for the diagnosis of complex nephrology cases. Can AI help nephrologists nail the correct diagnosis?

REFINe-ing AI’s Role in Nephrology Diagnosis
Background
Akshaya J
Too sweet to be true? Prophylactic SGLT2 ...

MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.

Too sweet to be true? Prophylactic SGLT2 inhibitors before cardiac surgery
Background
Cristina Adriana Popa
Buffering without benefit? The SODa-BIC study

This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?

Buffering without benefit? The SODa-BIC study

track

TRACK trial on Instagram

TRACK trial on Instagram

A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Cristina Popa

On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.

On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.

Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.

Track: El Resumen Visual

¿Puede rivaroxabán reducir los eventos cardiovasculares en la ERC avanzada?

El estudio TRACK comparó rivaroxabán a dosis bajas frente a placebo en pacientes con ERC estadio 4–5 y enfermedad renal en diálisis con alto riesgo cardiovascular.

Revisa nuestro más reciente resumen visual y acompáñanos en la próxima discusión de #NephJC.